Kaplan-Meier plots showing time taken to achieve CD4 T-cell counts >500 cells/µl following cART initiation.

<p>Kaplan-Meier plots showing time taken to achieve CD4 counts &gt;500cells/µl among (A) patients in the total cohort (n = 501) and patients with no evidence of virological failure (VF) (2 consecutive HIV RNA&gt;500copies/ml) throughout follow-up (n = 331) and (B) all patients (n = 501) stratified by baseline CD4 T-cell counts (&lt;100cells/µl, n = 99; 101–200cells/µl, n = 107; 201–350cells/µl, n = 172; &gt;350cells/µl, n = 123). Comparisons of survival curves were done using the Log-rank test (STATA 10.0).</p

Patient disposition.

<p>Patient disposition.</p

Demographic and clinical characteristics of patients from AHOD who met the inclusion criteria for this study.

<p>All parameters are median (IQR) unless otherwise stated.</p><p>cART-combination Antiretroviral therapy; MSM – men who have sex with men; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor (boosted and unboosted); NRTI – nucleoside reverse transcriptase inhibitor.</p><p>*Others included injecting drug use, transfusion and unrecorded.</p><p>PIs included Atazanavir (boosted and unboosted) (5%), Lopinavir/Ritonavir (11%), Indinavir (boosted and unboosted) (32%), Nelfinavir (27%), Ritonavir (10%), Saquinavir (boosted and unboosted) (13%), Tipranavir (1%), Fosamprenavir (1%); NNRTIs included Delavirdine (1%), Efavirenz (44%), Nevirapine(55%);</p

Predictors of time taken to achieve CD4 T-cells &gt;500 cells/µl (n = 501).

<p>*Reference category.</p><p>**Others included injecting drug use, transfusion and unrecorded.</p>#<p>For every 100-unit increase in square transformed baseline CD4 T-cell counts, the hazard of achieving a CD4 T-cell threshold of &gt;500cells/µl increased by 15%.</p><p>cART-combination Antiretroviral therapy; MSM – men who have sex with men; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor (boosted and unboosted) ; NRTI – nucleoside reverse transcriptase inhibitor; ADI – AIDS-defining illness; HBsAg – hepatitis B surface antigen; HCV Ab – hepatitis C antibody.</p

Predictors of time taken to achieve CD4 T-cells &gt;200 cells/µl (n = 196).

<p>*Reference category.</p><p>**Others included injecting drug use, transfusion and unrecorded.</p><p>cART-combination Antiretroviral therapy; MSM – men who have sex with men; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor (boosted and unboosted) ; NRTI – nucleoside reverse transcriptase inhibitor; ADI – AIDS-defining illness; HBsAg – hepatitis B surface antigen; HCV Ab – hepatitis C antibody.</p

Skillings-Mack and Wilcoxon signed-rank test (with Bonferroni adjustment) for FOXP3 data (see Table 2).

<p>Skillings-Mack and Wilcoxon signed-rank test (with Bonferroni adjustment) for FOXP3 data (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0039368#pone-0039368-t002" target="_blank">Table 2</a>).</p

Summary of the dose escalation trial. 1 dose unit = 1×10⁷ DC.

<p> <i>(√ = 1 dose unit infused via i.v route and  = 1 dose unit infused via i.d route).</i></p><p> <i>(Adapted from Gowans et al. (2010) J Hepatol; 53:599).</i></p

T cells expressing FOXP3.

<p>(<b>A</b>) Example of plots showing gate settings. (<b>B</b>) The frequency of FOXP3⁺ T cells at different time points, gating on CD3⁺ T cells. (<b>C</b>) Inverse correlation between the frequencies of FOXP3⁺ Treg and CEF-specific TNFα/IFNγ dual functional T cells.</p

Cytokine positive responses - a complete dataset from all patients.

<p>(<b>A</b>) Cytokine producer frequency (%, gating on viable CD3⁺ T cells) at baseline and different time points thereafter. The numbers on the x-axis (1, 2, 3, 4, 5 and 6) are the patient ID. Abbreviations: BL = Base Line; PI-2 = Prior to 2^nd Infusion; PI-3 = Prior to 3^rd Infusion, W = Week post final infusion. (<b>B</b>) The normalised MFI, corresponding to the responses detected in (A). (<b>C</b>) T cell quality in PT#4 and PT#5, depicted by the normalised MFI of cytokine positive responses. (<b>D</b>) The frequency (%) and normalised MFI over time in PT#3. (<b>E</b>) The dose and timing of DC infusion each patient received and the timing of sample collection. (<b>F</b>) Contribution of CD4 and CD8 T cells (please note the differences in scale) to the cytokine positive responses in PT#3.</p

The frequency (% within CD3⁺ T cells) of FOXP3⁺ Treg of the patients at various time points.

<p>The frequency (% within CD3⁺ T cells) of FOXP3⁺ Treg of the patients at various time points.</p